Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...
Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...
The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient in over-the-counter drugs for nasal congestion, stating it ...
Shares of Altimmune (NASDAQ:ALT) rallied 30% in afternoon trading after the company issued several business updates along ...
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA clears iRhythm's first 510(k ... The analyst maintains the Outperform rating on iRhythm Technologies stock. Price Action: IRTC stock is up 20.30% at $74.70 at last check Tuesday.
Denali Therapeutics (NASDAQ:DNLI) said it plans to file for FDA accelerated approval of its ... to nearly $1.3B by 2029 ...
Rhythm Technologies (Nasdaq:IRTC) announced that the FDA granted 510(k) clearance for Zio AT design modifications and ...
On Tuesday, Citi reaffirmed its Sell rating and a $26.00 stock price target for NASDAQ:PTCT, PTC Therapeutics (NASDAQ:PTCT). The focus of this confirmation was the U.S. Food and Drug Administration's ...
Piper Sandler and BTIG, on the other hand, have reiterated their neutral stance and Buy rating respectively, following the issuance of an FDA Form 483, which led to a review of the approval timeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback